{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-094622","form_type":"8-K","ticker":"ATNM","cik":"0001388320","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.316873+00:00","generated_at":"2026-05-30T05:15:39.427205+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Actinium appoints June Almenoff, M.D., Ph.D. to Board of Directors","bullets":["Dr. Almenoff brings over 25 years of biopharma leadership; previously President and CMO of Furiex (acquired by Actavis/AbbVie for $1.2B).","She will serve on the Nominating and Corporate Governance Committee; term as Class III director expires at 2025 annual meeting.","Granted options for 50,000 shares at $1.71, vesting 28% at 12 months then 2% monthly thereafter.","Appointment effective November 1, 2024; experienced in translational medicine, clinical development, and regulatory submissions."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-094622","json":"https://secwatch.observer/filing/0001213900-24-094622.json","markdown":"https://secwatch.observer/filing/0001213900-24-094622.md","text":"https://secwatch.observer/filing/0001213900-24-094622.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390024094622/0001213900-24-094622-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390024094622/ea022011301-8k_actinium.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:15:39.427205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23c89dce4e","claim":"June Almenoff was appointed as Director at Actinium Pharmaceuticals, Inc..","evidence_excerpt":"On November 1, 2024, June Almenoff, M.D., Ph.D., was appointed as a director of Actinium Pharmaceuticals, Inc. (the “Company”)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390024094622/0001213900-24-094622-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}